Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited reported significant advancements in their dendrimer-based therapeutics, with positive Phase 2 trial results for DEP® SN38 in cancers such as advanced colorectal and platinum-resistant ovarian cancer, showing better efficacy and tolerability than current treatments. The company also highlighted the potential of their DEP® platform in radiopharmaceuticals and reinforced their strategic focus on maximizing DEP® asset value, accelerating early asset development, and ensuring long-term sustainability. Starpharma ended the financial year with a healthy cash reserve and is actively pursuing a licensing deal for their DEP® assets while advancing towards clinical studies for their radiopharmaceuticals program.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
